August 11, 2025
3 min watch
Key takeaways:
- Arcascope makes use of sleep and circadian rhythm to determine the perfect time of day for most cancers remedy.
- The corporate was certainly one of 14 startups chosen for the 2025 CancerX Accelerator cohort.
Arcascope — a circadian well being firm — is leveraging its mixture of AI, mathematical fashions and wearable gadgets to evaluate how a affected person’s physique adjustments all through the day, and decide when most cancers remedy will likely be simplest.
“We’re harnessing how the physique adjustments over the course of the day to do a greater job of growing drugs,” Olivia Walch, PhD, the corporate’s founder and CEO, instructed Healio. “Lots of most cancers therapies are given with out consideration of what time of day they may work finest — we discover medication that failed as a result of they got on the mistaken time, after which we ‘rescue them’ for sufferers with most cancers.”
She added: “As we speak, oncologists would use this product together with their sufferers to assist work out the perfect time for them to take a drug. Sooner or later, we see this as [something] not only for oncology, however an throughout the board in drugs platform for serving to folks take management of timing of their physique. Lots of people assume we will’t observe anyone’s circadian clock with out doing an costly, invasive check. We’ve proven that’s not true.”
Arcascope was certainly one of simply 14 startups chosen for the 2025 CancerX Accelerator cohort, a gaggle of revolutionary digital well being and synthetic intelligence startups targeted on addressing vital challenges in oncology. This system is hosted by Moffitt Most cancers Heart and launched in collaboration with the Workplace of the Nationwide Coordinator for Well being Data Know-how and the Workplace of the Assistant Secretary for Well being.
The CancerX Accelerator program supplies collaborating startups with entry to business champions, skilled mentors and a variety of help, from product suggestions and pilot alternatives to potential industrial agreements.
“We have now confirmed that [Arcascope] may be very correct in a number of peer reviewed papers, and we will leverage it to assist folks work out the best time for his or her drug for them,” Walch stated. “We needed to be a part of CancerX Accelerator to get in contact with the important thing stakeholders in oncology and since becoming a member of CancerX, we now have began some actually thrilling collaborations.”
On this video, Walch explains the important thing the reason why she needed to take part within the CancerX Accelerator, the collaborations it has already offered to her and the corporate, and her recommendation for the 2026 CancerX Accelerator cohort.
Because the official media accomplice of the CancerX 2025 Accelerator cohort, Healio will showcase key breakthroughs and achievements via unique interviews with this 12 months’s startups in addition to alumni teams from the 2024 program.
Purposes for the 2026 CancerX Accelerator cohort will open Sept. 2, 2025, solely for CancerX members, with public purposes opening Sept. 9, 2025. Be a part of the CancerX group right here.
References:
For extra data:
Olivia Walch, PhD, may be reached on LinkedIn right here.
